ArticleBMC cancer2011
Prediction of outcome after diagnosis of metachronous contralateral breast cancer.
Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature.BioMed research international · 2014Pooled it
- Determining the Need for Metastatic Staging in Patients with Bilateral Breast Cancers.Current oncology (Toronto, Ont.) · 2024Article
- Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.Cancer reports (Hoboken, N.J.) · 2024Article
- Survival After Development of Contralateral Breast Cancer in Korean Patients With Breast Cancer.JAMA network open · 2023Article
- Article
- Effect of breast-conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer.Gland surgery · 2021Article
- Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series.European journal of breast health · 2020Article
- Article
- Long-term survival outcomes in invasive lobular carcinoma patients with and without preoperative MR imaging: a matched cohort study.European radiology · 2019Article
- Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.PloS one · 2019Article
- Natural History of Invasive Papillary Breast Carcinoma Followed for 10 Years: A Case Report and Literature Review.Case reports in medicine · 2017Article
- Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.Journal of cancer research and clinical oncology · 2016Article
- Article
- Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.Breast cancer research : BCR · 2015Article
- The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine.Genome medicine · 2015Article
- The molecular and clinicopathologic characteristics of bilateral breast cancer.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis.
methodsInformation on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints.
resultsThe cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group analysis, this effect was seen primarily in patients aged <50. By logistic regression analysis, patients diagnosed with BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to those who were symptomatic at diagnosis (p < 0.0001). Chemotherapy given after breast BC1 was a negative prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS.
conclusionsIn a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide biological explanations to these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.